Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric J Small

Showing results (31-40 of 361) with videos related to

Pageof 37
Sort By:
Expert Review of Anticancer Therapy|October 6, 2006
Sipuleucel-T (APC8015) for prostate cancerRosendo So-Rosillo, Eric J Small
Therapeutic Advances in Urology|December 22, 2018
Apalutamide in the treatment of castrate-resistant prostate cancer: evidence from clinical trialsVadim S Koshkin, Eric J Small
The Journal of Urology|April 17, 2002
Osteoporosis in men treated with androgen deprivation therapy for prostate cancerRobert W Ross, Eric J Small
Expert Opinion on Biological Therapy|August 21, 2007
Immunotherapy for prostate cancer using antigen-loaded antigen-presenting cells: APC8015 (Provenge)Andrea L Harzstark, Eric J Small
Current Opinion in Oncology|April 7, 2007
Prostate cancer update: 2006Amy M Lin, Eric J Small
The Urologic Clinics of North America|July 12, 2002
PC-SPES and prostate cancerWilliam K Oh, Eric J Small
Oncology (Williston Park, N.Y.)|October 18, 2014
Small-cell/neuroendocrine prostate cancer: a growing threat?Rahul R Aggarwal, Eric J Small
Current Opinion in Oncology|April 8, 2004
Advances in prostate cancerCharles J Ryan, Eric J Small
Future Oncology (London, England)|November 15, 2018
Apalutamide and its use in the treatment of prostate cancerHala T Borno, Eric J Small
Expert Opinion on Pharmacotherapy|March 24, 2010
Castrate-resistant prostate cancer: therapeutic strategiesAndrea L Harzstark, Eric J Small
Pageof 37

Showing results (31-40 of 361) with videos related to

Sort By:
Pageof 37
Expert Review of Anticancer Therapy|October 6, 2006
Sipuleucel-T (APC8015) for prostate cancerRosendo So-Rosillo, Eric J Small
Therapeutic Advances in Urology|December 22, 2018
Apalutamide in the treatment of castrate-resistant prostate cancer: evidence from clinical trialsVadim S Koshkin, Eric J Small
The Journal of Urology|April 17, 2002
Osteoporosis in men treated with androgen deprivation therapy for prostate cancerRobert W Ross, Eric J Small
Expert Opinion on Biological Therapy|August 21, 2007
Immunotherapy for prostate cancer using antigen-loaded antigen-presenting cells: APC8015 (Provenge)Andrea L Harzstark, Eric J Small
Current Opinion in Oncology|April 7, 2007
Prostate cancer update: 2006Amy M Lin, Eric J Small
The Urologic Clinics of North America|July 12, 2002
PC-SPES and prostate cancerWilliam K Oh, Eric J Small
Oncology (Williston Park, N.Y.)|October 18, 2014
Small-cell/neuroendocrine prostate cancer: a growing threat?Rahul R Aggarwal, Eric J Small
Current Opinion in Oncology|April 8, 2004
Advances in prostate cancerCharles J Ryan, Eric J Small
Future Oncology (London, England)|November 15, 2018
Apalutamide and its use in the treatment of prostate cancerHala T Borno, Eric J Small
Expert Opinion on Pharmacotherapy|March 24, 2010
Castrate-resistant prostate cancer: therapeutic strategiesAndrea L Harzstark, Eric J Small
Pageof 37